Jordi Remon, Tina Cascone, Solange Peters. "BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non–Small Cell Lung Cancer." Journal of Clinical Oncology, 2026. doi:10.1200/jco-25-02696